Genmab — Juli 2019
-
670 duer slet ikke, det er en stigning på 6% fra Q1 til Q2, der skal mere til, vi skel helst over 700
-
Jeg blev lidt nysgerrig omkring Blink og CD 47fandt så dette fra et amerikansk firma (Forty Seven): In June 2018, we entered into an asset purchase agreement with BliNK Biomedical SAS, or BliNK, pursuant to which we acquired all of BliNK’s assets relating to its research and development program for antibodies directed against CD47." Side 71 i dette https://ir.fortyseveninc.com/node/6501/html
-
Kunne man forestille sig at Genmab købte Halos rettigheder til Dara SQ?
-
Der står non-oncology ? https://ir.fortyseveninc.com/static-files/c858876f-5dcb-468b-b5e7-505b1b556b1a
-
Gary er nu klar til asct, takket være dara https://www.youtube.com/watch?v=y2DfLgcquY8
-
Haematologica article- Daratumumab Displays In Vitro And In Vivo Anti-Tumor Activity In Models Of B Cell Non-Hodgkin Lymphoma - http://www.haematologica.org/content/early/2019/07/09/haematol.2018.211904
-
Shiff. - undskyld , - men hvad forventer du. For mig at se er indsendelsen af Dara sc en rigtig god nyhed , og jeg vil mene at nye salgstal og Q2 fra J&J kan fremme forventninger til Q3 og Q4 . For mig er forventningerne at der snart ( og det er SNART ) at der fra de store spillere på markedet kommer reaktioner der bekræfter potentialet i Genmab's pipeline . ( my personal appointment ) Dara is the future in oncology.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
